<DOC>
	<DOCNO>NCT00014248</DOCNO>
	<brief_summary>RATIONALE : Adenosine triphosphate may decrease weight loss improve muscle strength patient advance solid tumor . PURPOSE : Phase I trial study effectiveness adenosine triphosphate control loss weight loss muscle mass patient advance solid tumor .</brief_summary>
	<brief_title>Adenosine Triphosphate Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine individualized maximum tolerate dose adenosine triphosphate patient advance solid tumor . - Determine safety regimen patient . - Determine pharmacokinetics regimen patient . - Determine effect regimen quality life patient . - Determine influence regimen cancer cachexia term weight change , percentage body fat , voluntary muscle strength , plasma marker patient . - Determine effect regimen tumor burden patient . OUTLINE : This dose-escalation study . Patients receive adenosine triphosphate ( ATP ) IV 8 hour day 0 . Treatment repeat weekly total 8 course absence disease progression unacceptable toxicity . Each patient receive escalate dos ATP individual maximum tolerate dose ( MTD ) determine . The MTD define dose precede patient experience least grade 3 ( least grade 2 cardiac ischemia arrhythmia ) toxicity . Weight measure baseline week 1-8 , 10 , 13 . Percentage body fat skeletal muscle strength measure baseline week 2 , 4 , 8 , 10 , 13 . Quality life assess baseline week 2 , 4 , 8 , 10 , 13 . Patients follow week 10 13 . PROJECTED ACCRUAL : A maximum 13-24 patient accrue study .</detailed_description>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced solid tumor curable conventional therapy Brain metastasis allow adequately control radiotherapy PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 60100 % Life expectancy : At least 12 week Hematopoietic : WBC least 3,500/mm^3 Absolute neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : SGOT SGPT great 3 time normal Bilirubin great 2.0 mg/dL Renal : Creatinine great 1.5 mg/dL Creatinine clearance great 60 mL/min BUN great 25 mg/dL Cardiovascular : Adequate cardiovascular function No congestive heart failure ( New York Heart Association class III IV heart disease ) No angina pectoris AND/OR No significant arrhythmia No myocardial infarction within past 6 month No clinically significant ischemic cardiac disease currently treatment No clinically significant conduction system disease absence pacemaker ( e.g. , sick sinus syndrome , second third degree atrioventricular block ) Pulmonary : Adequate pulmonary function No clinical evidence acute chronic obstructive pulmonary disease FEV1 least 50 % predict Arterial oxygen tension least 90 % pulse oximetry breathing room air No asthma OR No evidence 20 % reversibility FEV1 albuterol therapy Other : Not pregnant nursing Fertile patient must use effective contraception No history severe adverse reaction adenosine No uncontrolled medical illness No average daily pain score least 5 simple Visual Analogue Self pain assessment ( 010 ) scale PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy recover Surgery : Not specify Other : At least 30 day since prior investigational therapy At least 14 day since prior longterm theophylline , dipyridamole , dipyridamole/aspirin therapy No concurrent longterm theophylline , dipyridamole , dipyridamole/aspirin therapy No concurrent maintenance antianginal drug therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>cachexia</keyword>
</DOC>